Trial Profile
A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 3 fixed doses of EAA-090 [perzinfotel] in adult outpatients with neuropathic pain associated with diabetic neuropathy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2013
Price :
$35
*
At a glance
- Drugs Perzinfotel (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- 16 Mar 2007 New trial record.